Theravance Biopharma, Inc. (TBPH): R&D Expense
$37.41M
Year ended 2025-12-31
$26.01M
Trailing 12 months to 2026-06-30
-16.1%
3-year compound annual growth
-32.2%
5-year compound annual growth
-11.7%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.41M | -0.6% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $37.64M | -7.3% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $40.62M | -35.9% | 2025-03-07, From 2023-01-01 |
| 2022-12-31 | $63.39M | -67.3% | 2024-03-01, From 2022-01-01 |
| 2021-12-31 | $193.66M | -25.8% | 2023-03-01, From 2021-01-01 |
| 2020-12-31 | $260.95M | +19.0% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $219.25M | +8.9% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $201.35M | +15.8% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $173.89M | +22.7% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $141.71M | +9.7% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $129.16M | -23.4% | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | $168.52M | +39.8% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $120.58M | +5.8% | 2016-03-11, From 2013-01-01 |
| 2012-12-31 | $114.00M | n/a | 2015-03-13, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $37.41M | -0.6% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $12.74M | -69.7% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $137.00M | +1.8% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $67.11M | +17.4% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $13.70M | +13.9% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $19.96M | +62.1% |
| Xencor Inc (XNCR) | 2025-12-31 | $239.43M | +5.2% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.26M | -3.7% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $416.03M | +22.6% |
Compare TBPH, ZVRA, ZYME, URGN side by side · Screen every company in Pharmaceutical Preparations ↗